Trading Signals: ADAP Stock Price Prediction and Forecast (Mon. Oct. 26, 2015 - Fri. May. 28, 2021)(Adaptimmune Therapeutics plc)
| ADAP latest price $5.4300 (-1.27%) ($5.2100 - $5.5600) on Fri. Nov. 16, 2018. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 5.56% (three month average) | RSI | 47 | Latest Price | $5.4300(-1.27%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | ADAP declines -2.5% a day on average for past five trading days. | Weekly Trend | ADAP declines -5.5% a week on average for past two weeks. | Market Behavior | Value stock rally for large cap. Normal for small cap. | Correlated ETFs | Broad market will support ADAP advance at 0% a week (0% probability) SMH(17%) GDXJ(12%) JETS(11%) FXI(9%) ICLN(9%) | Factors Impacting ADAP price | ADAP will decline at least -2.78% in a week (0% probabilities). XLP(-10%) XLV(-8%) VIXM(-8%) VXX(-6%) IFRA(-6%) | | | | | Relative Volatility | | | | Market Trend Strength | -2.78% (StdDev 5.56%) | Hourly BBV | 0 () | Intraday Trend | -0.9% | | | |
|
1 - 5 Day Possible Target | $-25.8(-575.14%) | Resistance Level | $6.38 | 5 Day Moving Average | $5.78(-6.06%) | 10 Day Moving Average | $6.17(-11.99%) | 20 Day Moving Average | $6.38(-14.89%) | To recent high | -61.7% | To recent low | 0% | Market Cap | $840m | | | | Adaptimmune Therapeutics Plc engages in the development of novel cancer immunotherapy products. Its specific peptide enhanced affinity receptor platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. The company was founded by Bent K. Jakobsen, James Julian Noble, and Helena Katrina Tayton-Martin in 2008 and is headquartered in Abingdon, the United Kingdom. |